Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

Abstract To compare enzalutamide (E) and abiraterone acetate (AA) in terms of efficacy, survival to characterize prognostic factors affecting metastatic castration-resistant prostate cancer (mCRPC) patients. A total 250 patients treated with E or AA 5 centers were included. The number no specific antigen (PSA) decline was higher the group than that group, proportion a PSA ? 50% (p = 0.020). Radiological progression free (rPFS) overall (OS) significantly longer when compared < 0.001 p 0.027, respectively). In rPFS both pre- post-docetaxel settings 0.010 0.003, OS similar pre-docetaxel setting; but setting, had 0.021). multivariate analysis performed whole patient we found good for treatment, being 75 years while there factor OS. With PFS, seems be more suitable mCRPC setting AA.